Amgen Inc. (AMGN)
Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) to Release Earnings on Thursday
Amgen (NASDAQ: AMGN - Get Free Report) will likely be posting its Q1 2026 results after the market closes on Thursday, April 30th. Analysts expect Amgen to post earnings of $4.74 per share and revenue of $8.5772 billion for the quarter. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Investors may review the information
Boston Trust Walden Corp Has $23.54 Million Stock Holdings in Amgen Inc. $AMGN
Boston Trust Walden Corp grew its holdings in Amgen Inc. (NASDAQ: AMGN) by 390.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 71,905 shares of the medical research company's stock after buying an additional 57,235 shares during the quarter. Boston
Amgen (AMGN) Laps the Stock Market: Here's Why
In the most recent trading session, Amgen (AMGN) closed at $355.3, indicating a +1.69% shift from the previous trading day.
Amgen's lung cancer drug tarlatamab wins China approval
Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines said on Friday on WeChat.
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
Amgen (AMGN) closed at $355.6 in the latest trading session, marking a +1.66% move from the prior day.
Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs
Amgen Inc. and Eli Lilly and Company occupy leading positions in the immune-mediated inflammatory diseases treatment market. Moreover, AMGN hopes to grab a piece of the GLP-1s market from LLY. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the rival.
Amgen (AMGN) Beats Stock Market Upswing: What Investors Need to Know
Amgen (AMGN) reached $349.81 at the closing of the latest trading day, reflecting a +2.89% change compared to its last close.
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy
Amgen Inc. is rated a solid Buy, supported by robust revenue growth, pipeline strength, and recent FDA approvals despite looming patent expiries on legacy drugs. Tepezza's successful Phase 3 subcutaneous trial enhances its competitive position in the Thyroid Eye Disease - TED - market, targeting expanded patient access and chronic use. AMGN's 2026 guidance projects $37–$38.4bn in revenue and non-GAAP EPS of $21.6–$23, with a forward P/E of ~17x and a diverse late-stage pipeline.
Is Amgen (AMGN) Outperforming Other Medical Stocks This Year?
Here is how Amgen (AMGN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.
Here's Why Amgen (AMGN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease
Amgen's subcutaneous Tepezza hits phase III goals in thyroid eye disease, matches IV efficacy and offers faster dosing that could expand access.
